Fischer Y, Thomas J, Rösen P, Kammermeier H
Institute of Physiology, Medical Faculty Rheinisch-Westfälische Technische Hochschule, Aachen, Germany.
Endocrinology. 1995 Feb;136(2):412-20. doi: 10.1210/endo.136.2.7835271.
The effects of the antidiabetic drug metformin on glucose transport were investigated in freshly isolated heart muscle cells from healthy and streptozotocin-diabetic rats. In vivo treatment of diabetic rats with metformin failed to affect the basal and insulin-stimulated rate of glucose transport measured in isolated cells. In vitro exposure to therapeutic concentrations (< or = 10(-4) M) of metformin did not influence glucose transport, even upon incubation times up to 5 h or in the presence of high glucose (20 nM). In contrast, higher metformin concentrations produced an 8- to 12-fold increase in glucose uptake (with a lag of 90 min, and a maximum at 180 min and approximately 5 mM). In the presence of submaximal insulin concentrations (< or = 3.10(-10) M), the effects of metformin (5 mM) and of insulin were more than additive, whereas, at saturating insulin concentrations (10(-8) M), partial additivity was observed. Like insulin, metformin caused an approximately 1.6-fold increase in the content of both glucose transporter isoforms GLUT1 and GLUT4 in the plasma membrane of cardiac myocytes, with a corresponding decrease in an intracellular membrane fraction. cAMP-elevating treatments depressed the metformin-, but not the insulin-dependent glucose uptake, by 20-30%. In myocytes from diabetic rats, the rate of metformin-activated glucose transport was similar to that of cells from control animals, whereas basal and insulin-stimulated transport were substantially diminished. Finally, metformin (5 mM) induced a slight depression of oxygen consumption and energy metabolism of myocytes (as determined by measuring their level of energy-rich phosphates) comparable to the effects of hypoxia in rat hearts. In conclusion, these data do not provide evidence in favor of the hypothesis that glucose uptake by muscle tissue represents the site of metformin's therapeutic action in vivo. On the other hand, the large, insulin-independent effect of metformin at high concentrations (approximately mM) in vitro may be related to the action of hypoxia and occurs through a redistribution of glucose carriers from an intracellular locus to the plasma membrane. The mechanism (or signal) involved in metformin's action is likely to differ from that triggered by insulin and is not impaired in the diabetic state.
在从健康大鼠和链脲佐菌素诱导的糖尿病大鼠新鲜分离的心肌细胞中,研究了抗糖尿病药物二甲双胍对葡萄糖转运的影响。用二甲双胍对糖尿病大鼠进行体内治疗,未能影响在分离细胞中测得的基础葡萄糖转运速率和胰岛素刺激的葡萄糖转运速率。体外暴露于治疗浓度(≤10⁻⁴ M)的二甲双胍,即使孵育时间长达5小时或在高葡萄糖(20 nM)存在的情况下,也不会影响葡萄糖转运。相反,较高浓度的二甲双胍使葡萄糖摄取增加了8至12倍(有90分钟的延迟,在180分钟时达到最大值,约为5 mM)。在亚最大胰岛素浓度(≤3.10⁻¹⁰ M)存在的情况下,二甲双胍(5 mM)和胰岛素的作用具有超相加性,而在饱和胰岛素浓度(10⁻⁸ M)时,则观察到部分相加性。与胰岛素一样,二甲双胍使心肌细胞质膜中葡萄糖转运蛋白异构体GLUT1和GLUT4的含量增加了约1.6倍,而细胞内膜部分的含量相应减少。提高cAMP的处理使二甲双胍依赖性而非胰岛素依赖性的葡萄糖摄取降低了20%至30%。在糖尿病大鼠的心肌细胞中,二甲双胍激活的葡萄糖转运速率与对照动物细胞的相似,而基础和胰岛素刺激的转运则显著降低。最后,二甲双胍(5 mM)使心肌细胞的耗氧量和能量代谢略有降低(通过测量其富含能量的磷酸盐水平确定),这与大鼠心脏缺氧的影响相当。总之,这些数据不支持肌肉组织摄取葡萄糖是二甲双胍体内治疗作用部位这一假说。另一方面,二甲双胍在体外高浓度(约mM)时具有较大的、不依赖胰岛素的作用,可能与缺氧作用有关,并且是通过葡萄糖载体从细胞内位点重新分布到质膜而发生的。二甲双胍作用所涉及的机制(或信号)可能与胰岛素触发的机制不同,并且在糖尿病状态下不会受损。